All Stories

  1. A comparative study of blood cell count in four automated hematology analyzers: An evaluation of the impact of preanalytical factors
  2. Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective U.S. Insurance Claims Study
  3. Clinical identification of malignant pleural effusions
  4. Benralizumab increases time to recurrent exacerbations in COPD patients on triple therapy with frequent exacerbations and an eosinophilic phenotype
  5. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
  6. Effect of COVID-19 on non-cystic fibrosis bronchiectasis exacerbation rates: a retrospective claims study
  7. Effect of benralizumab on recurrent COPD exacerbations
  8. The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing
  9. Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial
  10. KRAS signaling in malignant pleural mesothelioma
  11. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects
  12. The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma
  13. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases
  14. The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
  15. Thoracic Ultrasound for guiding pleurodesis in malignant pleural effusion: a randomised trial
  16. Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation
  17. A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma
  18. S46 Identification of pleural infection bacterial patterns. The oxford pleural infection metagenomics study
  19. “Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study.” John P. Corcoran, Ioannis Psallidas, Stephen Gerry, Francesco Piccolo, Coenraad F. Koegelenberg, Tarek Saba, Cyrus Daneshvar...
  20. Management of Indwelling Tunneled Pleural Catheters
  21. Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments
  22. Application of machine learning algorithms to predict loss of asthma control: A post-hoc analysis of INCONTRO study
  23. Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis
  24. Correlation between clinic and remote FEV1 and FeNO measurements; post hoc analysis of the INCONTRO study
  25. The association between pleural fluid exposure and survival in malignant pleural mesothelioma: a retrospective cohort study in 761 patients
  26. Studying the biological properties of pleural fluid: pleural fluid alone is adequate for cancer cell proliferation in vitro
  27. Identification of pleural infection microbiological patterns by applying next generation sequencing and bioinformatics analysis
  28. Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
  29. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
  30. Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology...
  31. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study
  32. Clinical identification of malignant pleural effusions
  33. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
  34. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
  35. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions
  36. Clinically important associations of pleurodesis success in malignant pleural effusion: Analysis of the TIME1 data set
  37. Osteopontin drives KRAS-mutant lung adenocarcinoma
  38. S13 The microbiology of pleural infection, an approach based on 16s RRNA gene next generation sequencing
  39. Survival in patients with malignant pleural effusion undergoing talc pleurodesis
  40. Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
  41. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight
  42. The microbiology of pleural infection in adults: a systematic review
  43. Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial
  44. A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease
  45. A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial with Withdrawal Design of AZD1419, a Toll-9 Agonist in Adults with Eosinophilic, Moderate to Severe Asthma
  46. Interpreting pleural fluid results
  47. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial
  48. Novel mouse model of indwelling pleural catheter in mice with malignant pleural effusion
  49. Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter
  50. Palliative care in mesothelioma: Are current services RESPECT-able enough?
  51. Response
  52. Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?
  53. Prospective Analysis of the Predictive Value of Sonographic Pleural Fluid Echogenicity for the Diagnosis of Exudative Effusion
  54. S133 Breathlessness post-drainage predicts survival in patients with malignant pleural effusion
  55. S130 Human mesothelioma cell lines developed from malignant pleural effusions as tools to develop novel therapies and guide personalised medicine
  56. P257 Is mesothelioma associated with increased risk of indwelling pleural catheter-related septated pleural effusion?
  57. S131 Novel model of indwelling pleural catheter in mice with malignant pleural effusion
  58. P258 Retrospective analysis of whether prior talc pleurodesis attempt affects subsequent IPC-related autopleurodesis or not
  59. P260 The biological effect of tissue plasminogen (t-PA) activator and DNase intrapleural delivery in pleural infection patients
  60. Thoracic Ultrasound as an Early Predictor of Pleurodesis Success in Malignant Pleural Effusion
  61. A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study)
  62. Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations
  63. The Hospital and Patient Burden of Indwelling Pleural Catheters: A Retrospective Case Series of 210 Indwelling Pleural Catheter Insertions
  64. Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients
  65. Does the sonographic presence and severity of pleural fluid septation have an impact on clinical outcomes in pleural infection? - Data from the Pleural Infection Longitudinal Outcome Study (PILOT)
  66. Does talc increase risk of non-draining septated pleural effusion after indwelling pleural catheter insertion?
  67. Predictors of pleurodesis success
  68. The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.
  69. The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients
  70. Multiple ascending inhaled doses of AZD8871 in healthy males
  71. Activity and Outcomes From a Dedicated Pleural On-Call Service
  72. Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians
  73. ERS/EACTS statement on the management of malignant pleural effusions
  74. ERS/EACTS statement on the management of malignant pleural effusions
  75. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis
  76. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion
  77. Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion
  78. Chest drain size: Does it matter?
  79. Preliminary results of the Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study
  80. S24 A phase i feasibility study in establishing the role of ultrasound-guided pleural biopsies in pleural infection (the audio study)
  81. S129 Does inflammation predict successful pleurodesis? a post hoc analysis from the time 1 trial
  82. S128 Exploring the behaviour of mesothelioma in a post hoc analysis from the time 1 trial
  83. P239 Is a pleural on-call service beneficial?
  84. P234 Patient and fluid characteristics associated with non-draining malignant pleural effusion
  85. P233 Thoracic ultrasonography as a predictor of pleurodesis success in malignant pleural effusion
  86. Thoracic involvement in IgG4-related disease in a UK-based patient cohort
  87. Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial
  88. Late Breaking Abstract - A phase I feasibility study in establishing the role of ultrasound-guided pleural biopsies in pleural infection (The AUDIO study)
  89. Late Breaking Abstract - Prognostic and therapeutic markers of malignant pleural effusion – The PROMISE study
  90. Retrospective analysis of survival time in malignant pleural effusion requiring IPC insertion
  91. Case series to analyse whether echogenicity always reveals underlying exudate or not
  92. LSC - 2017 - Mouse lung adenocarcinoma cell lines as tools to identify novel lung cancer genes
  93. Respiratory training in Greece
  94. Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma
  95. Treatment of limited disease small cell lung cancer: the multidisciplinary team
  96. Assessment of patient-reported outcome measures in pleural interventions
  97. Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
  98. Management of malignant pleural effusion: challenges and solutions
  99. Mutant KRAS promotes malignant pleural effusion formation
  100. NRAS destines tumor cells to the lungs
  101. Ultrasound in the management of pleural disease
  102. Provision of Day-Case Local Anesthetic Thoracoscopy
  103. Chest Drain Size: the Debate Continues
  104. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
  105. P4 A prospective assessment of the clinical utility of intercostal artery identification in pleural intervention
  106. S94 Biological markers of favourable prognosis and successful pleurodesis for malignant pleural effusion
  107. P2 Incorporation of an in-depth thoracic ultrasound assessment into routine pre-procedural evaluation of patients with pleural effusions
  108. S7 Mouse lung adenocarcinoma cell lines reveal PRL2C2 as a novel lung tumour promoter
  109. S8 Osteopontin as an airway epithelial tumour promoter
  110. Effectiveness of chemical pleurodesis in spontaneous pneumothorax recurrence prevention: a systematic review
  111. Biological markers of successful pleurodesis for malignant pleural effusion
  112. Long-term outcome of patients with non-specific pleuritis on thoracoscopic or ultrasound-guided pleural biopsies
  113. Lent score validation on patients with malignant pleural effusion
  114. LSC Abstract – Osteopontin as an airway epithelial tumor promoter
  115. “Advanced medical interventions in pleural disease.” Rahul Bhatnagar, John P. Corcoran, Fabien Maldonado, David Feller-Kopman, Julius Janssen, Philippe Astoul and Najib M. Rahman. Eur Respir Rev 2016; 25: 199–213.
  116. Landmark studies for targeted treatments in lung cancer
  117. Advances in pleural disease
  118. Malignant pleural effusion: from bench to bedside
  119. Safe site selection for chest drain insertion by trainee physicians — Implications for medical training and clinical practice
  120. Always Worth Another Look? Thoracic Ultrasonography before, during, and after Pleural Intervention
  121. 30 Patient experience of a telephone nodule follow-up clinic
  122. Medical thoracoscopy: Survey of current practice-How successful are medical thoracoscopists at predicting malignancy?
  123. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion
  124. S20 Primary Result of the 1st Therapeutic Interventions in Malignant Effusion (TIME1) Trial: A 2 × 2 factorial, randomised trial of chest tube size and analgesic strategy for pleurodesis in malignant pleural effusion
  125. P179 The Effectiveness of Chemical Pleurodesis Agents in Spontaneous Pneumothorax: A Systematic Review: Abstract P179 Table 1
  126. P207 Thoracic involvement in IgG4-related disease
  127. Diagnostic value of radiological imaging pre‐ and post‐drainage of pleural effusions
  128. Draining pleural effusions before radiological imaging does not improve diagnostic capability
  129. Intrapleural tPA increases pleural fluid output in pleural infection, independent of chest X-ray opacification
  130. Patient-related outcome measurements in pleural diseases
  131. LSC Abstract – A requirement for mast cells in malignant pleural effusion
  132. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growthin vivo
  133. Individualised management of malignant pleural effusion
  134. Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection
  135. Iatrogenic injury to the intercostal artery: aetiology, diagnosis and therapeutic intervention
  136. Mast cells mediate malignant pleural effusion formation
  137. Intercostal chest drain insertion by general physicians: attitudes, experience and implications for training, service and patient safety
  138. Interleukin-27 improves the ability of adenosine deaminase to rule out tuberculous pleural effusion regardless of pleural tuberculosis prevalence
  139. Ultrasound-guided pneumothorax induction prior to local anaesthetic thoracoscopy: Table 1
  140. A 63-year-old man with a recurrent right-sided pleural effusion: Figure 1
  141. Management of Parapneumonic Effusions and Empyema
  142. P175 Measurement Of Air Leak Post-thoracic Surgery: Implications For Medical Management Of Pneumothorax
  143. S45 How Successful Are Medical Thoracoscopists At Predicting Malignancy?
  144. S40 Improving The Patient Journey: Thoracic Ultrasonography As An Adjunct To Decision Making And Diagnostic Pathways In Pleural Disease
  145. P177 Patient-related Outcome Measurements In Pleural Effusions
  146. P111 Procedural Experience, Training Opportunities And Attitudes Towards Intercostal Chest Drain Insertion: Variations Between Consultants, Trainees And Medical Sub-specialties
  147. S117 Survival In Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From 6 Uk Centres
  148. Tuberculous pleuritis secondary toMycobacterium bovisin a veterinarian
  149. Physician-Based Ultrasound-Guided Biopsy for Diagnosing Pleural Disease
  150. Image of the month: A misleading chest X-ray - not all opacification is effusion
  151. Staphylococcus aureusbio-products: New biological roles for a pleurodesis agent
  152. Reexpansion Pulmonary Edema Following Local Anesthetic Thoracoscopy
  153. Paracetamol and ibuprofen block hydrothorax absorption in mice
  154. Interleukin-18 is up-regulated in infectious pleural effusions
  155. Interleukin‐17A is involved in bacteria‐related acute pleural inflammation
  156. Inhibition Of Osteopontin Modulates Tumor-Stimulated Immune Response And Suppresses Mesothelioma Progression
  157. Abstract 2873: Opposing effects of NF-κB inhibition during chemical lung carcinogenesis
  158. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion
  159. Opposing effects of bortezomib-induced nuclear factor- B inhibition on chemical lung carcinogenesis
  160. Neutralization of Tumor Necrosis Factor Bioactivity Ameliorates Urethane-Induced Pulmonary Oncogenesis in Mice
  161. A sulindac analogue is effective against malignant pleural effusion in mice
  162. Static and dynamic mechanics of the murine lung after intratracheal bleomycin
  163. Secreted Phosphoprotein-1 Enhances Urethane-induced Lung Carcinogenesis
  164. Osteopontin Is Important For Malignant Pleural Effusion Formation
  165. Dexamethasone acutely accelerates pleural fluid absorption in mice hydrothoraces
  166. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study
  167. Protective Effects of Mastic Oil FromPistacia LentiscusVariationChiaAgainst Experimental Growth of Lewis Lung Carcinoma
  168. Osteopontin is upregulated in malignant and inflammatory pleural effusions
  169. Etanercept-induced pleuropericardial lupus-like syndrome
  170. The Angiopoietin/Tie2 Axis Mediates Malignant Pleural Effusion Formation
  171. A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion
  172. Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion
  173. Tumor Necrosis Factor-  Promotes Malignant Pleural Effusion
  174. The efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE)